We report a case of advanced PMEC, a female patient with high-grade tumor tissue differentiation and EML4-ALK fusion variants E20:A20 (V2), who was in treating with lorlatinib as the first line therapy and observed progression-free survival (PFS) over 14 months as of June 8, 2024. Here, ALK is linked to neoplasm.